Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by KingWhatsion Nov 05, 2010 5:40am

439 Views

Post# 17662348

RE: 2 possible outcome

Sprott is not a market maker. They are investment managers. They buy speculative stocks on behalf of their clients. The people mainly responsible are the investment brokers who participated in the private placements.

Those folks didn't invest millions just to give us suckers a chance to make a few bucks, they invested to make money and that's exactly what they are doing. What we see is just the normal day to day trading in a risky penny stock.

The only thing that will move this stock up is real revenue - or the confirmed prospect of future revenue. In this case, a real oil well with real oil in it. That's what we are waiting for so just sit back and wait.

If the hole proves out, we win. If not, we lose.

Bullboard Posts

Southern Ontario mineral processing operation receives green fund support